vTv Therapeutics Inc. (VTVT) · Nov 5, 2026 · Earnings

vTv Therapeutics earnings beat as Phase 3 trial reaches enrollment

Beat — EPS $(0.94) vs published consensus around $(1.07)

vTv Therapeutics earnings beat on EPS while confirming CATT1 enrollment is complete and cash should last through the mid-2027 data readout.

vTv Therapeutics is a late-stage biotech built around cadisegliatin, an oral adjunctive treatment for type 1 diabetes now in Phase 3 CATT1, with the company trying to reach a mid-2027 efficacy readout before needing to fund the next major step. That positioning was already established before this release.

The quarter modestly beat the financial bar, but this is not a commercial inflection. Third-quarter EPS was $0.94 below zero versus published estimates ranging roughly from $1.07 to $1.16 below zero, while revenue was zero against an estimate of about $0.33 million. The EPS beat is mainly a narrower-than-expected loss, not evidence of revenue generation; vTv remains a development-stage company with no approved commercial product.

MetricQ3 2026Q3 2025Consensus
EPS (Net Loss)$(0.94)$(1.08)$(1.07)
Revenue (Income Statement)$—$—$0.33M
R&D expense (Financial Results)$7.5M$7.0M
G&A expense (Financial Results)$4.9M$3.7M
Cash and equivalents (Balance Sheet)$77.2M$88.9M at Dec. 31, 2025

The important business milestone is real, but mostly already known. Enrollment in the pivotal CATT1 study is complete, with 166 participants randomized across two cadisegliatin doses and placebo; topline results remain targeted for mid-2027. 〔0〕 〔1〕 Because enrollment completion was announced in October, this release confirms rather than newly reveals the milestone. The new detail is that the company has also started the smaller Hybrid CATT1 study for patients using automated insulin-delivery systems.

Cash coverage reduces the near-term funding overhang, without removing execution risk. Cash fell to $77.2 million from $88.9 million at year-end, while quarterly R&D and G&A costs both increased as the Phase 3 program moved forward. Still, management says the current balance should fund operations through the anticipated CATT1 readout. 〔2〕 That matters because the company’s central value-bearing event is now the clinical result, not another financing before the readout.

The broader pipeline adds optionality, but not near-term validation. FDA Orphan Drug Designation for HPPD may help partnering discussions in sickle cell disease, yet the program remains preclinical and secondary to cadisegliatin. The release therefore strengthens the existing development path modestly, rather than changing the company’s overall risk profile.

Bottom line: This is a slight positive earnings update: the loss was better than expected and the company remains funded toward its pivotal mid-2027 data. But the main clinical milestones were already public, so the filing advances the existing story rather than rewriting it.

What to watch next

CATT1 topline results expected mid-2027

Original filing on SEC EDGAR

vTv Therapeutics earnings beat as Phase 3 trial reaches enrollment | VTVT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.